Abstract:
This invention provides methods of using phagocytic cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using phagocytic cells to identify markers of diseases or conditions.
Abstract:
This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of kidney-associated diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of kidney-associated diseases or conditions.
Abstract:
Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent- specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.
Abstract:
Disclosed is a method for detecting the presence of aberrant proliferating cells within a non-proliferating tissue in a mammal. Also disclosed are methods useful in diagnosis or therapy of aberrant proliferating cells.
Abstract:
This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of cardiovascular diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of cardiovascular diseases or conditions.
Abstract:
A method of making a radiolabeled pyrimidine nucleoside or nucleotide is described. In the method, an aqueous solution (i) a radioactive iodide, bromide, chlorine or astatide ion and (ii) a water soluble halomercuri pyrimidine nucleoside or nucleotide is contacted with an oxidizing agent, whereby a water soluble pyrimidine nucleoside or nucleotide labeled with radioactive iodine, bromine, chlorine or astatine is formed. Kits suitable for practicing the method are also disclosed.
Abstract translation:描述了制备放射性标记的嘧啶核苷或核苷酸的方法。 在该方法中,将水溶液(i)放射性碘化物,溴化物,氯或ast ide ide离子和(ⅱ)水溶性卤代核苷嘧啶核苷或核苷酸与氧化剂接触,由此将水溶性嘧啶核苷或放射性标记的核苷酸 形成碘,溴,氯或ast。。 还公开了适用于实施该方法的套件。
Abstract:
The method of making radioiodinated pyrimidine nucleoside or nucleotide which comprises contacting a water-insoluble halomercuri pyrimidine nucleoside or nucleotide with an aqueous medium containing a dissolved radioactive iodide ion and an oxidizing agent, the molar amounts of said nucleoside or nucleotide and said oxidizing agent being in excess of the molar amount of said iodide, whereby water-soluble radioactive iodinated pyrimidine nucleoside or nucleotide is formed in solution, and separating residual water-insoluble halomercuri pyrimidine nucleoside or nucleotide from said solution.
Abstract:
Kits and methods provide for the isolation of white blood cells from bodily fluids. In one exemplary aspect, a method for isolating white blood cells from blood includes the act of adding a blood sample to a separation tube having a distal end, a proximal end, and a valve located proximate said proximal end, said valve being configured to transition between at least first, second, and third positions. The method also includes the act of removably attaching a cap to the distal end, centrifuging the separation tube with the valve in the first position, removing the cap at the distal end of the separation tube and removably attaching a first syringe to the proximal end, switching the valve to the second position and withdrawing, via the first syringe, a red blood cell sediment. The method also includes the act of switching the valve to the first position and removing the first syringe, adding a small volume of buffer to the separation tube, removably attaching a cap to the distal end and centrifuging the separation tube and removing the cap at the distal end of the separation tube and removably attaching a second syringe to the proximal end. Additional acts include switching the valve to the second position, withdrawing the remaining red blood cell sediment via the second syringe and switching the valve to the first position and removing the second syringe.
Abstract:
Dihydrorhodamines can be made by reduction of rhodamines and can be covalently halogenated by conventional procedures. The compounds are useful as labelling, imaging, and therapeutic agents for mammalian cells.